Short answer
Moderna (MRNA) filed its Q2 2026 10-Q quarterly report on Jul 31, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $145M (up 2.1% year over year) with net income of −$782M.
Q2 2026 key financials · XBRL
- Revenue
- $145M
- +2.1% YoY · −62.7% QoQ
- Net income
- −$782M
- +5.2% YoY · +41.8% QoQ
- Operating margin
- -562.1%
- EPS (diluted)
- −$1.96
- +7.5% YoY · +42.4% QoQ
Source: XBRL data from the Moderna (MRNA) Q2 2026 10-Q on SEC EDGAR. USD.
Moderna Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No risk-factors section provided; supplied text covers equity repurchases, insider trading arrangements, exhibits, and signatures
- Compliance risk: executive Rule 10b5-1 plans authorize potential sales through September 17, 2027
- Governance risk: Bancel plan covers exercise of options totaling 1,393,916 shares before February 26, 2027
- Financial risk: $1.7 billion remains available under the share-repurchase authorization with no expiration date
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Moderna quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.